Imatinib mesylate induced pityriasis rubra pilaris like rash
DOI:
https://doi.org/10.66344/jpad.31.4.2021.1728Abstract
Pityrisis Rubra Pilaris (PRP) is an inflammatory keratinisation disorder with unknown etiology characterized by orange-red erythema, circumscribed keratosis, and branny scales, and palmoplantar keratoderma. There have been very few case reports which suggest drugs as an inciting or triggering factor for PRP. Imatinib is a Tyrosine Kinase inhibitor that is being used in several diseases notably chronic myeloid leukemia ( CML) and Gastrointestinal stromal tumors ( GIST). In this case report, we described a diagnosed case of CML with ABL-BCR positivity on oral Imatinib 400mg who developed generalized erythema with an orange hue and follicular keratosis with islands of normal skin. She was diagnosed as a case of PRP clinically and dermoscopically. Imatinib was stopped and she was started on 40 mg steroids which were tapered and stopped. The rash subsided in 1 week subsequently and did not recur in 6 months.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
